Choroideremia Market

Market Overview:

The 7 major choroideremia markets are expected to exhibit a CAGR of 4.22% during 2024-2034.

The choroideremia market has been comprehensively analyzed in IMARC's new report titled "Choroideremia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Choroideremia refers to a rare genetic disorder that affects the retinal cells, a part of the eye responsible for capturing images and sending them to the brain for processing. This condition causes progressive degeneration of the choroid, a membrane of blood vessels beneath the retina, which can ultimately lead to complete blindness. The symptoms of the ailment typically appear in childhood or adolescence and worsen gradually over the years. Some common indications of this illness include night blindness, reduced peripheral vision, central vision loss, etc. The progression of the disease and the severity of symptoms can vary widely among patients. The diagnosis of choroideremia typically involves a combination of clinical evaluation, family history analysis, and specific diagnostic tests. An ophthalmologist will also perform a comprehensive eye examination to assess the patient's visual acuity, peripheral vision, and the condition of the retina and choroid. An optical coherence tomography imaging study is further recommended to obtain cross-sectional pictures of the eye that help in visualizing and assessing the structural changes in the retina, such as thinning of the outer layers.

The increasing cases of mutations in the gene responsible for producing specific proteins that are essential for normal cellular function are primarily driving the choroideremia market. In addition to this, the inflating application of anti-vascular endothelial growth factor (VEGF) therapy, since it involves injecting therapeutic agents directly into the targeted site, thereby reducing abnormal blood vessel growth in the retina, is also creating a positive outlook for the market. Moreover, the widespread adoption of low-intensity laser techniques owing to their various advantages, such as preventing retinal cells from degeneration and apoptosis as well as slowing down the disease progression, is further bolstering the market growth. Apart from this, the escalating utilization of steroid therapy to manage inflammation and autoimmune responses in individuals suffering from the ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which involves introducing a functional copy of the defective gene into the retinal cells to improve vision, is expected to drive the choroideremia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the choroideremia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for choroideremia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the choroideremia market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the choroideremia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the choroideremia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current choroideremia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the choroideremia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the choroideremia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the choroideremia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of choroideremia across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of choroideremia by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of choroideremia by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with choroideremia across the seven major markets?
• What is the size of the choroideremia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of choroideremia?
• What will be the growth rate of patients across the seven major markets?
   

Choroideremia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for choroideremia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the choroideremia market?
• What are the key regulatory events related to the choroideremia market?
• What is the structure of clinical trial landscape by status related to the choroideremia market?
• What is the structure of clinical trial landscape by phase related to the choroideremia market?
• What is the structure of clinical trial landscape by route of administration related to the choroideremia market?